Show simple item record

dc.contributor.authorAmjad, A.
dc.contributor.authorHopkins, N.
dc.contributor.authorKamposioras, Konstantinos
dc.contributor.authorLim, Kok Haw Jonathan
dc.date.accessioned2021-10-28T09:26:17Z
dc.date.available2021-10-28T09:26:17Z
dc.date.issued2021en
dc.identifier.citationAmjad A, Hopkins N, Kamposioras KV, Lim KHJ. 1578P Clinical outcomes of patients with cancer who tested positive for COVID-19 hospitalised in a UK district general hospital. Vol. 32, Annals of Oncology. Elsevier BV; 2021. p. S1139.en
dc.identifier.doi10.1016/j.annonc.2021.08.1571en
dc.identifier.urihttp://hdl.handle.net/10541/624725
dc.description.abstractBackground Individuals diagnosed with cancer have been particularly affected by the COVID-19 pandemic. Most of the relevant information so far has come from tertiary cancer centres and less is known of the outcomes of patients in District General Hospitals (DGH). In this audit, we aimed to investigate the clinical outcomes of patients with cancer who tested positive for COVID-19 and were admitted in a DGH. Methods Electronic records of patients admitted at Tameside General Hospital (TGH) (>500 beds) between March 2020�March 2021 were reviewed retrospectively. Clinical outcomes of those who tested positive for COVID-19 and factors relating to death were analysed. Cox regression and Kaplan-Meier survival analyses were performed (SPSS v26.0). Results Within the 12-month study period, there were 2417 inpatients who tested positive for COVID-19 at TGH. Of 235 individual patients with cancer admitted during this period, 14% (n=33) tested positive. Median age was 75 (68;81) years; majority female (67%). The most prevalent primary site of cancer were lung (21%) and breast (12%). Most were ECOG PS 1 (39%) or PS 2 (36%), and had high Charlson Comorbidity Index (median 5 (3;6), range 0-10). 24% of patients were on curative treatment, 39% palliative treatment, 18% best supportive care and 18% not on treatment. Types of treatment included chemotherapy (37%), hormonal treatment (26%), radiotherapy (21%) and immunotherapy (5%). On average, patients were admitted at least once (range 0-4) prior to positive test for COVID-19. At last follow-up, there were n=664/2417 (27%) and n=22/33 (67%) deaths in the non-cancer and cancer patient subgroups, respectively. The median time from diagnosis of COVID-19 to death/censor date was 44 (4;85) days. In univariate Cox regression analysis, only ECOG PS was significantly correlated with death, HR 1.523 (95% CI 1.064-2.181, p=0.022). Conclusions The outcomes of our cohort of patients with cancer who tested positive for COVID-19 and hospitalised were poor. The high comorbidity burden and poor ECOG PS could potentially account for this rather than the recent oncological treatment. Acute oncology input to general medical teams treating cancer patients with COVID-19 is pivotal for best possible outcomes for patients.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.annonc.2021.08.1571en
dc.titleClinical outcomes of patients with cancer who tested positive for COVID-19 hospitalised in a UK district general hospitalen
dc.typeOtheren
dc.contributor.departmentMedicine, Tameside and Glossop Integrated Care NHS Foundation Trust, Manchester, UKen
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen]
refterms.dateFOA2021-11-03T10:26:24Z


Files in this item

Thumbnail
Name:
AnnOncAmjad.pdf
Size:
84.56Kb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record